MiMedx commenced patient enrollment in a Phase III Investigational New Drug clinical trial of AmnioFix® Injectable in the treatment of Achilles Tendonitis.
Enrollment, slightly delayed from the previously-expected 4Q17 launch, will include ~158 subjects in this prospective, double blinded, randomized controlled trial of Micronized dehydrated Human Amnion Chorion Membrane Injection vs. saline placebo. Following completion, MiMedx plans to submit a Biologic License Application to FDA.
Sources: MiMedx; ORTHOWORLD Inc.
MiMedx commenced patient enrollment in a Phase III Investigational New Drug clinical trial of AmnioFix® Injectable in the treatment of Achilles Tendonitis.
Enrollment, slightly delayed from the previously-expected 4Q17 launch, will include 58 subjects in this prospective, double blinded, randomized controlled trial of Micronized dehydrated...
MiMedx commenced patient enrollment in a Phase III Investigational New Drug clinical trial of AmnioFix® Injectable in the treatment of Achilles Tendonitis.
Enrollment, slightly delayed from the previously-expected 4Q17 launch, will include ~158 subjects in this prospective, double blinded, randomized controlled trial of Micronized dehydrated Human Amnion Chorion Membrane Injection vs. saline placebo. Following completion, MiMedx plans to submit a Biologic License Application to FDA.
Sources: MiMedx; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.